Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03112005 · ClinicalTrials.gov registry record
Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool
A clinical trial of Diabetic Macular Edema and Diabetic Retinopathy, sponsored by Eyenuk.
- Completed
- Registry status
- 942
- Enrollment target
- 1
- Study location
NCT03112005 is a study of Diabetic Macular Edema and Diabetic Retinopathy that has completed, run by Eyenuk. The registered enrollment target is 942 participants, below the 3,779-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03112005, a study of Diabetic Macular Edema and Diabetic Retinopathy, has completed, sponsored by Eyenuk.
- COMPLETED
- Registry status
- 942 participants
- Enrollment target
- 1
- Study location
Study Summary
More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommended for all diabetic patients since vision loss can be prevented with laser photocoagulation and anti-VEGF treatment if DR is diagnosed in its early stages. Currently, the number of clinical personnel trained for DR screening is orders of magnitude smaller than that needed to screen the large, growing diabetic population. Therefore, to meet this large unmet need for DR screening, a fully-automated computerized DR screening system is necessary. EyeArt is an automated screening device designed automatically analyze color fundus photographs of diabetic patients to identify patients with referable or vision threatening DED. This study is designed to assess the safety and efficacy of EyeArt.
Conditions Studied
Interventions
- PROCEDURE Color fundus photography
- DRUG Mydriatic Agent
Study Locations (1)
California
- Los Angeles Biomedical Research Institute - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2017-04-17 |
| Est. Completion | 2018-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03112005
The ClinicalTrials.gov registry entry for NCT03112005 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 942 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,779-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (75% lower). The listed sponsor is Eyenuk, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Color fundus photography is the first listed.
NCT03112005 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03112005 about?
NCT03112005 is a clinical study titled "Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool". More than 29 million people in the US are living with diabetes, many of whom will develop diabetic retinopathy (DR) or diabetic macular edema (DME) collectively known as diabetic eye disease (DED), the leading cause of vision loss and blindness in working-age adults. Annual eye screening is recommen...
What is the current status of trial NCT03112005?
This trial is currently completed. The enrollment target is 942 participants. The study started on 2017-04-17. Estimated completion is 2018-05-31.
What conditions does trial NCT03112005 study?
This clinical trial studies the following conditions: Diabetic Macular Edema, Diabetic Retinopathy, Diabetic Eye Problems.
What interventions are being tested in trial NCT03112005?
The interventions under investigation include: Color fundus photography (PROCEDURE), Mydriatic Agent (DRUG).
Who is sponsoring clinical trial NCT03112005?
This trial is sponsored by Eyenuk, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03112005 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.